Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for serious diseases, including rare lung infections and inflammatory conditions. Its flagship product, ARIKAYCE, treats nontuberculous mycobacterial lung disease using liposomal inhalation technology. The company also advances pipeline candidates in gene therapy, pulmonary hypertension, and inflammatory diseases, leveraging proprietary platforms, strategic licensing, and a global manufacturing and patent portfolio.
This description was generated via AI from an annual report. Updated about 1 year ago.